■特比萘芬可能会导致亚急性皮肤红斑狼疮(SCLE),并分析其临床特点。
■我们收集了1997年至2023年有关特比萘芬诱导的SCLE的文献,以进行回顾性分析。包括37例患者(33例女性和4例男性)。
■患者的中位年龄为49.5岁(范围18-79),发病时间为5周(范围1-12)。SCLE主要表现为环状红斑(83.3%),鳞状红斑(44.4%)和斑丘疹性红斑(13.9%)。组织病理学表现以淋巴细胞浸润为主(55.6%),角化过度(38.9%)和角化细胞坏死(38.9%)。阳性免疫学指标主要包括抗核抗体(100.0%),抗Ro/SSA抗体(94.1%)和抗La/SSB抗体(72.2%)。既往病史通常包括光敏性(33.3%),炎性疾病(33.33%)和红斑狼疮(12.1%)。特比萘芬停药和局部皮质类固醇治疗后,症状在中位时间35天(范围7-84)内完全缓解。全身性皮质类固醇,羟氯喹和免疫抑制剂。随访12个月(范围1.5-48)内未观察到复发。
■这些结果表明,应根据临床症状全面诊断特比萘芬引起的SCLE,组织病理学表现,免疫学参数,和过去的病史。当SCLE发生时,特比萘芬应立即停用,而全身和局部皮质类固醇联合羟氯喹可能是一种有效的治疗方法。
UNASSIGNED: Terbinafine may cause subacute cutaneous lupus erythematosus (SCLE), and we aimed to analyze its clinical characteristics.
UNASSIGNED: We collected literature on terbinafine-induced SCLE from 1997 to 2023 for retrospective analysis. Thirty-seven patients (33 females and 4 males) were included.
UNASSIGNED: The patients have a median age of 49.5 years (range 18-79) and onset time of 5 weeks (range 1-12). SCLE is mainly manifested as annular erythematous (83.3%), scaly erythematous (44.4%), and maculopapular erythematous (13.9%). Mainly, histopathological manifestations are lymphocytic infiltrate (55.6%), hyperkeratosis (38.9%) and keratinocyte necrosis (38.9%). Positive immunological parameters mainly include antinuclear antibody (100.0%), anti-Ro/SSA antibody (94.1%), and anti-La/SSB antibody (72.2%). Past medical history usually includes photosensitivity (33.3%), inflammatory disease (33.33%), and lupus erythematosus (12.1%). Symptoms are completely resolved within a median time of 35 days (range 7-84) after discontinuation of terbinafine and treatment with topical corticosteroids, systemic corticosteroids, hydroxychloroquine, and immunosuppressant. No recurrence was observed within 12 months (range 1.5-48) of follow-up.
UNASSIGNED: These results suggest that terbinafine-induced SCLE should be comprehensively diagnosed based on clinical symptoms, histopathological manifestations, immunological parameters, and past medical history. Terbinafine should be immediately discontinued when SCLE occurs, while systemic and topical corticosteroids combined with hydroxychloroquine may be an effective treatment.